Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. (Q46410598)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

title

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

2

Patrick Wen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

3

Timothy Cloughesy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Susan M Chang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Harry Greenberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

David Schiff

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Charles Conrad

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Karen Fink

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

H Ian Robins

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Jeffrey Raizer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Kenneth Hess

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Ken Aldape

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Kathleen R Lamborn

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

John Kuhn

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Janet Dancey

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

Michael D Prados

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

North American Brain Tumor Consortium and the National Cancer Institute

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

publication date

1 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

Investigational New Drugs

30 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

357-361

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16012795 AND SRC:MED&resulttype=core&format=json

PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis

30 December 2019

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10637-005-1444-0

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

12 December 2020

Studies on the mechanism of resistance to rapamycin in human cancer cells

1 reference

12 December 2020

Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.

1 reference

12 December 2020

The epidermal growth factor receptor in glioblastoma: genomic amplification, protein expression, and patient survival data in a therapeutic trial.

1 reference

12 December 2020

AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression

1 reference

12 December 2020

Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

1 reference

12 December 2020

Response criteria for phase II studies of supratentorial malignant glioma

1 reference

12 December 2020

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

1 reference

12 December 2020

Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy.

1 reference

12 December 2020

Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo

1 reference

12 December 2020

PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.

1 reference

12 December 2020

Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis.

1 reference

12 December 2020

MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells

1 reference

12 December 2020

Mechanisms of resistance to rapamycins

1 reference

12 December 2020

Pten signaling in gliomas

1 reference

12 December 2020

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

12 December 2020

TOR, a central controller of cell growth

1 reference

12 December 2020

Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells

1 reference

12 December 2020

Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

1 reference

12 December 2020

Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs.

1 reference

12 December 2020